SOPHiA GENETICS Closes $57.5 Million Public Offering

SOPHiA GENETICS has completed the closing of its previously announced underwritten public offering, raising total gross proceeds of $57.5 million before expenses, according to a press release. The offering was oversubscribed, leading the underwriters to fully exercise their option to purchase additional shares.

The company sold 12,104,900 ordinary shares at a public price of $4.75 per share. This total included 1,578,900 shares issued upon the full exercise of the underwriters’ option. All shares in the offering were sold by the company.

TD Cowen acted as the lead book running manager for the transaction. Guggenheim Securities served as book running manager, while BTIG and Craig Hallum acted as lead managers. The offering was made under an effective registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission.

SOPHiA GENETICS is a health technology company that develops AI based solutions for precision medicine, including its SOPHiA DDM platform for analyzing genomic and multimodal data.